Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Study of HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

NCT04676477 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT04676477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04676477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Study of HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 11, 2021
Completion date
April 30, 2027
Enrollment
246 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)